GEN Exclusives

More »

GEN News Highlights

More »
Nov 28, 2007

Covance to Divest Cardiac Safety Services to eResearchTechnology for $35M

  • Covance decided to sell its centralized electrocardiogram (ECG) business to eResearchTechnology (eRT) for $35 million in cash.

    Simultaneously, Covance also signed a marketing agreement to offer its clients cardiac safety services through eRT's centralized ECG platform over the next 10 years. Covance stands to receive up to $14 million more related to the transferred backlog and revenues generated from new contracts. Additionally, the firms expects to obtain certain referral fees over the term of the marketing agreement.

    Covance reports that the ECG business accounted for less than 2% of its annual net revenues. The company’s other segments cover a range of offerings to the pharma, biotech, food and dietary supplements, environmental, and research industries. These include services related to antibodies, biomarkers, lab management, pharmacogenomics, and postmarketing surveillance.

    “The transaction,” points out Joe Herring, chairman and CEO, “allows Covance's management team to focus more attention and investments on growing our service offerings in the larger markets we serve.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?